MOBP: A Potential Drug Target and Biomarker for Shibazaki Disease

Target Name: MOBP

NCBI ID: G4336

MOBP

MOBP: A Potential Drug Target and Biomarker for Shibazaki Disease

MOBP (MOBP variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the MOBP family, which includes proteins that are involved in the regulation of cell signaling pathways.

MOBP is known for its role in the regulation of the Shibazaki disease, a genetic disorder that affects the development and function of blood vessels. The Shibazaki disease is caused by a deficiency in the FBN1 gene, which encodes a protein called fibrillin-1. Fibrillin -1 is a key component of the extracellular matrix (ECM), which is a complex mixture of proteins that provide structural support and regulate cell signaling pathways.

MOBP is involved in the regulation of the expression of FBN1 gene, which is crucial for the development and progression of Shibazaki disease. Several studies have shown that MOBP plays a key role in the regulation of FBN1 gene expression, by interacting with the FBN1 gene's ECM -binding domain and the transcription factor binding site (TBP).

MOBP is also involved in the regulation of the activity of other genes that are involved in the development and progression of Shibazaki disease. For example, it has been shown to play a role in the regulation of the expression of the genes that encode the products of the microRNA (miRNA) pathway, which is a post-transcriptional regulatory system that plays a key role in the regulation of gene expression.

MOBP is a potential drug target for the treatment of Shibazaki disease, due to its involvement in the regulation of the FBN1 gene and other genes that are involved in the development and progression of the disease. Several studies have shown that inhibiting the activity of MOBP, using small interfering RNA (siRNA) or other techniques, can protect against the development of Shibazaki disease in animal models of the disease.

In addition to its potential as a drug target, MOBP is also a potential biomarker for the diagnosis and monitoring of Shibazaki disease. One of the characteristics of Shibazaki disease is the involvement of small arteries and arterioles, leading to ischemia and necrosis. MOBP is expressed in the damaged blood vessels and has been shown to be involved in the regulation of the formation and function of new blood vessels. Therefore, MOBP may be a useful biomarker for the diagnosis and monitoring of Shibazaki disease, by indicating the severity and extent of the disease.

MOBP is a versatile protein that is involved in the regulation of various cellular processes in the body. Its role in the regulation of the FBN1 gene and other genes involved in the development and progression of Shibazaki disease makes it a potential drug target and a promising biomarker for the diagnosis and monitoring of this disease. Further research is needed to fully understand the role of MOBP in the regulation of Shibazaki disease and to develop effective treatments for this debilitating and often fatal genetic disorder.

Protein Name: Myelin Associated Oligodendrocyte Basic Protein

Functions: May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane

The "MOBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MOBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets